Loading clinical trials...
Loading clinical trials...
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Subjects With Mild or Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Conditions
Interventions
JNJ-56021927
Locations
2
United States
Knoxville, Tennessee, United States
San Antonio, Texas, United States
Start Date
August 13, 2015
Primary Completion Date
February 9, 2017
Completion Date
February 9, 2017
Last Updated
February 3, 2025
NCT07324616
NCT04271488
NCT05484206
NCT06952634
NCT07428525
NCT06841315
Lead Sponsor
Aragon Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions